Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 14/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 4/20 | 0.37 |
| ▸ | HTR7 | P34969 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 4/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17097206 | 0.93 | HTR6 (0.42) | HTR6CA12CA1CA2CA9 | |
| SCHEMBL17102220 | 0.88 | CA12 (0.43) | HTR6CA12CA1CA2CA9 | |
| SCHEMBL17096626 | 0.86 | HTR6 (0.41) | HTR6CA12CA1CA2CA9 | |
| SCHEMBL17096888 | 0.86 | HTR6 (0.42) | HTR6CA12CA1CA2CA9 | |
| SCHEMBL17096777 | 0.84 | HTR6 (0.44) | HTR6CA12CA1CA2CA9 | |
| SCHEMBL17097172 | 0.84 | HTR6 (0.45) | HTR6CA12CA1CA2CA9 | |
| SCHEMBL17120433 | 0.84 | HTR6 (0.38) | HTR6CA12CA1CA2CA9 | |
| SCHEMBL17097279 | 0.84 | LMNA (0.41) | HTR6CA12CA1CA2CA9 | |
| SCHEMBL17096742 | 0.83 | HTR6 (0.45) | HTR6HTR2AHTR7DRD2CYP3A4 | |
| SCHEMBL17102217 | 0.83 | HTR6 (0.41) | HTR6CA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3119763-A1 | NOVEL 3-INDOL SUBSTITUTED DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | Iteos Therapeutics (BE) | 2017-01-25 | — | — | EP | disclosed |
| WO-2015140717-A9 | NOVEL 3-INDOL SUBSTITUTED DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | ITEOS THERAPEUTICS (BE) | 2016-03-24 | — | — | WO | disclosed |
| US-20150266857-A1 | NOVEL 3-INDOL SUBSTITUTED DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | ITEOS THERAPEUTICS (BE) | 2015-09-24 | — | — | US | disclosed |
| WO-2015140717-A1 | NOVEL 3-INDOL SUBSTITUTED DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | ITEOS THERAPEUTICS (BE) | 2015-09-24 | — | — | WO | disclosed |
| US-20150266857-A1 | NOVEL 3-INDOL SUBSTITUTED DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | ITEOS THERAPEUTICS (BE) | 2015-09-24 | — | — | US | disclosed |
| US-20150266857-A1 | NOVEL 3-INDOL SUBSTITUTED DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | ITEOS THERAPEUTICS (BE) | 2015-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150266857-A1 | NOVEL 3-INDOL SUBSTITUTED DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | TDO2, IDO1, IDO2 | HTR6 47/4885CA12 4186/4885CA1 3346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.